• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens lead…
Market Samachar is a news aggregator. This article was originally published by Jnj.com. Tap the button above to read the full story on their site.